Literature DB >> 16970838

Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.

Margalida Rotger1, Chantal Csajka, Amalio Telenti.   

Abstract

Variable antiretroviral therapy (ART) drug response likely reflects the combined influence of environment, underlying disease, concurrent drugs, and genetics. Gender exerts modest or negligible effects on ART disposition, and it is expected to have limited clinical implication, although it should be accounted for in large population studies. Ethnic denominations have, with the notable exception of efavirenz, no clear influence on ART disposition. Exploration of genetic factors might offer a better comprehension to the largely unpredictable and unresolved variability in ART concentrations and related toxicity or treatment outcome. Despite the negative perception of genetic research among the general public, this type of investigation is now widely accepted by concerned parties: patients, relatives, and study volunteers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16970838     DOI: 10.1007/bf02696655

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  51 in total

1.  Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.

Authors:  Diane R Mould; Xiaoping Zhang; Keith Nieforth; Miklos Salgo; Neil Buss; Indravadan H Patel
Journal:  Clin Pharmacol Ther       Date:  2005-06       Impact factor: 6.875

2.  Differences in plasma binding of drugs between Caucasians and Chinese subjects.

Authors:  H H Zhou; A Adedoyin; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

3.  Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.

Authors:  K M L Crommentuyn; B S Kappelhoff; J W Mulder; A T A Mairuhu; E C M van Gorp; P L Meenhorst; A D R Huitema; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

4.  Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

Authors:  Vincent Jullien; Jean-Marc Tréluyer; Elisabeth Rey; Patrick Jaffray; Anne Krivine; Laurence Moachon; Agnès Lillo-Le Louet; Anne Lescoat; Nicolas Dupin; Dominique Salmon; Gérard Pons; Saïk Urien
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Authors:  David W Haas; Laura M Smeaton; Robert W Shafer; Gregory K Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victor De Gruttola; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; Alfred L George; John P Donahue; Richard B Kim
Journal:  J Infect Dis       Date:  2005-11-01       Impact factor: 5.226

6.  Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.

Authors:  Karl Brendel; Mayeule Legrand; Anne-Marie Taburet; Gabriel Baron; Cécile Goujard; France Mentré
Journal:  Fundam Clin Pharmacol       Date:  2005-06       Impact factor: 2.748

7.  Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

Authors:  Marc Pfister; Line Labbé; Scott M Hammer; John Mellors; Kara K Bennett; Susan Rosenkranz; Lewis B Sheiner
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.

Authors:  Marc Pfister; Line Labbé; Jian-Feng Lu; Scott M Hammer; John Mellors; Kara K Bennett; Susan Rosenkranz; Lewis B Sheiner
Journal:  Clin Pharmacol Ther       Date:  2002-08       Impact factor: 6.875

9.  Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.

Authors:  Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

10.  Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

Authors:  Courtney V Fletcher; Hongyu Jiang; Richard C Brundage; Edward P Acosta; Richard Haubrich; David Katzenstein; Roy M Gulick
Journal:  J Infect Dis       Date:  2004-03-16       Impact factor: 5.226

View more
  12 in total

1.  Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

Authors:  Charles S Venuto; Katie Mollan; Qing Ma; Eric S Daar; Paul E Sax; Margaret Fischl; Ann C Collier; Kimberly Y Smith; Camlin Tierney; Gene D Morse
Journal:  J Antimicrob Chemother       Date:  2014-08-25       Impact factor: 5.790

2.  Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.

Authors:  Haoming Zhang; Chitra Sridar; Cesar Kenaan; Hemali Amunugama; David P Ballou; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2011-06-09       Impact factor: 4.030

3.  Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.

Authors:  Weerawat Manosuthi; Somnuek Sungkanuparph; Preecha Tantanathip; Wiroj Mankatitham; Aroon Lueangniyomkul; Supeda Thongyen; Boonchuay Eampokarap; Sumonmal Uttayamakul; Pawita Suwanvattana; Samroui Kaewsaard; Kiat Ruxrungtham
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

4.  Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.

Authors:  Almudena Sánchez; Salvador Cabrera; Dolores Santos; M Paz Valverde; Aurelio Fuertes; Alfonso Domínguez-Gil; María J García
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

5.  Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation.

Authors:  Awewura Kwara; Margaret Lartey; Isaac Boamah; Naser L Rezk; Joseph Oliver-Commey; Ernest Kenu; Angela D M Kashuba; Michael H Court
Journal:  J Clin Pharmacol       Date:  2009-07-23       Impact factor: 3.126

6.  Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials.

Authors:  Meghan Coakley; Emmanuel Olutayo Fadiran; L Jo Parrish; Rachel A Griffith; Eleanor Weiss; Christine Carter
Journal:  J Womens Health (Larchmt)       Date:  2012-07       Impact factor: 2.681

7.  Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.

Authors:  Mona Arab-Alameddine; Aurélie Fayet-Mello; Rubin Lubomirov; Michael Neely; Julia di Iulio; Andrew Owen; Marta Boffito; Matthias Cavassini; Huldrych F Günthard; Katharina Rentsch; Thierry Buclin; Manel Aouri; Amalio Telenti; Laurent Arthur Decosterd; Margalida Rotger; Chantal Csajka
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

8.  Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008.

Authors:  Zhihui Dou; Jiahong Xu; Jin Hua Jiao; Ye Ma; Stephen Durako; Lan Yu; Yan Zhao; Fujie Zhang
Journal:  PLoS One       Date:  2011-08-16       Impact factor: 3.240

9.  Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.

Authors:  Jackson K Mukonzo; Joel S Owen; Jasper Ogwal-Okeng; Ronald B Kuteesa; Sarah Nanzigu; Nelson Sewankambo; Lehana Thabane; Lars L Gustafsson; Colin Ross; Eleni Aklillu
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

10.  Superior Effects of Antiretroviral Treatment among Men Who have Sex with Men Compared to Other HIV At-Risk Populations in a Large Cohort Study in Hunan, China.

Authors:  Shu Su; Xi Chen; Limin Mao; Jianmei He; Xiuqing Wei; Jun Jing; Lei Zhang
Journal:  Int J Environ Res Public Health       Date:  2016-03-08       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.